Work

Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.4556

Authors: Ronald C. Chen, Marion Feuilly, Jie Meng, Johanna Lister, Florence Marteau, Michael J. Morris, Daniel J. George, Toni K. Choueiri

Institutions: University of North Carolina at Chapel Hill, Ipsen (France), Memorial Sloan Kettering Cancer Center, Duke University, Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889809106

Cites:

Cited by: 6

Related to: 10